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AbstrACt
Introduction Women who choose to conceive a baby with 
a partner living with HIV or a partner whose HIV serostatus 
is unknown in HIV-endemic settings need prevention 
strategies to mitigate HIV acquisition during conception 
and pregnancy.
Methods and analysis We are conducting a single-
arm longitudinal study offering oral tenofovirdisoproxil 
fumarate/emtricitabine (TDF/FTC) as pre-exposure 
prophylaxis (PrEP) for periconception use to 350 HIV-
uninfected women in KwaZulu-Natal, South Africa. PrEP 
is offered as part of woman-centred safer conception 
programme that promotes couples-based HIV counselling 
and testing, antiretroviral therapy for partners who 
are HIV-infected, treatment for sexually transmitted 
infections and safer conception strategies, such as limiting 
condomless sex to peak fertility. We enrol HIV-uninfected 
women who are not currently pregnant, in a stable 
relationship (≥6 months) with a partner living with HIV 
or of unknown serostatus, and personal or partner plans 
for pregnancy in the next 12 months. We follow enrolled 
women for 12 months. Women who become pregnant 
are followed through pregnancy outcome, independent of 
their decisions regarding PrEP use. The primary objective 
of the study is to evaluate the uptake of and adherence 
to PrEP during the periconception period and pregnancy. 
Secondary outcomes include the uptake of other safer 
conception strategies. We also measure clinical outcomes 
including HIV seroconversion rates and pregnancy and 
infant outcomes. Finally, we will explore conduct and 
evaluate qualitative interviews in 25 participants to further 
inform our conceptual framework for periconception PrEP 
uptake and adherence among HIV-exposed women in 
South Africa.
Ethics and dissemination The protocol has been 
approved by the Human Research Ethics Committee at 
the University of the Witwatersrand (Johannesburg, South 
Africa) and the Institutional Review Board of Partners 
Healthcare (Boston, Massachusetts, USA). Study findings 
will be made available to interested participants. Results 
will be presented to local health officials and stakeholders 
at meetings. Investigators will share the results at 
meetings and in manuscripts. De-identified quantitative 
data will be made available.
trial registration number The protocol is registered 
with the South African Health Products Regulatory 
Agency (SAHPRA, formerly known as the Medicine 
Controls Council, MCC#20170131) and  ClinicalTrials. gov 
(NCT03194308); Pre-results.
IntroduCtIon
In HIV-endemic settings, many HIV-unin-
fected women choose to conceive a baby 
with a partner living with HIV or whose 
serostatus is not known.1–4 For a woman who 
cannot depend on a partner to test, initiate 
and adhere to ART, and suppress HIV RNA, 
condomless sex puts her at risk of acquiring 
HIV and increases the risk of perinatal 
transmission to her child.5 In South Africa, 
HIV incidence has declined since 2012, but 
women of reproductive age have the highest 
incidence at 0.93%.6 Even with the roll-out 
of test and treat antiretroviral therapy (ART) 
policies in South Africa, in some settings, 
strengths and limitations of this study
 ► This study will objectively measure uptake of and 
adherence to pre-exposure prophylaxis (PrEP) 
during conception and pregnancy.
 ► This study will evaluate the use of PrEP during preg-
nancy in South Africa where tenofovir disoproxil fu-
marate/emtricitabine is currently contraindicated in 
pregnancy.
 ► Enrolling women who may be exposed to HIV during 
conception attempts, but without requiring PrEP use, 
allows for evaluation of uptake.
 ► Enrolling women independent of their partners al-
lows for evaluation of adherence outside of mutual-
ly disclosed HIV-serodifferent partnerships.
 ► We will not test male partners’ HIV-serostatus or 
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HIV incidence among women continues to rise even as 
incidence declines among men,7 reflecting ongoing chal-
lenges to supporting men living with HIV to engage and 
remain in care.8–12 
Preventing HIV infection among women of reproduc-
tive age is the first pillar of reducing perinatal transmis-
sion.13 Although pregnant women living with HIV are a 
major focus of services to prevent perinatal transmission, 
HIV prevention prior to pregnancy receives relatively 
little attention. The contribution of intended conception 
to incident HIV infection is important in many HIV-en-
demic settings given the importance of having children, a 
lack of programmes addressing periconception transmis-
sion and high HIV prevalence.14
Daily, oral tenofovir disoproxil fumarate/emtricitabine 
(TDF/FTC) for pre-exposure prophylaxis (PrEP) dramat-
ically reduces a woman’s risk of HIV acquisition and may 
be an important female-controlled option for reducing 
the risk of periconception HIV acquisition.15 16 Evidence 
suggests it is safe to use during pregnancy.17 Under-
standing whether daily, oral PrEP is feasible for unin-
fected women seeking pregnancy is critical to reducing 
HIV incidence among women and their children.
Placebo-controlled trials identified adherence as a 
major challenge to long-term PrEP use among women.18 
However, women are eager for prevention strategies that 
allow for conception,19–21 and we hypothesise that adher-
ence to a proven prevention strategy, for a limited time 
with the motivation to have a healthy child, will confer 
the drug levels required to prevent HIV transmission. 
Supporting our hypothesis is the finding that women had 
a high adherence prior to conception in clinical trials and 
demonstration projects of PrEP.19 22–24
Our conceptual framework is based on an ecological 
framework published by van der Straten et al and adapted 
based on our periconception risk behaviour conceptual 
framework.25–27 This framework assumes that uninfected 
women who want to have a child with an infected or 
unknown serostatus partner will experience individual, 
couple and community-level factors that influence PrEP 
initiation and adherence behaviour. At the individual 
level, she may have excellent knowledge of safer concep-
tion strategies, be optimistic about PrEP efficacy and 
perceive herself to be at high risk for acquiring HIV. 
However, on the dyadic level, she and her partner may 
not communicate or trust one another, making it hard for 
her to adhere to daily medication. If she feels that child-
lessness and/or being HIV-infected is highly stigmatised 
in the community, then she may be more motivated to 
participate in periconception PrEP. Our mixed methods 
data will allow us to develop this framework to inform 
interventions for women seeking HIV-prevention during 
periconception and pregnancy.
This manuscript describes the ZINK protocol. ‘Zivikele 
ngaphambi kokukhulelwa’ means, ‘Protecting yourself before 
pregnancy’ in isiZulu. This project will inform whether 
daily, oral PrEP is a feasible component of comprehen-
sive HIV prevention for South African women who intend 
to conceive a baby and may be exposed to HIV. Given 
the repercussions of acquiring HIV during conception 
and pregnancy, periconception PrEP is an important step 




The Zivikele ngaphambi kokukhulelwa (ZINK) or Protecting 
yourself before pregnancy study is a single-arm longitudinal 
study offering safer conception counselling to HIV-ex-
posed women in Durban, South Africa. The safer concep-
tion package emphasises the importance of couples-based 
HIV counselling and testing (CHCT), ART for the 
infected partner, treatment for sexually transmitted 
infections (STIs), and safer conception strategies, such 
as limiting sex without condoms to peak fertility. We also 
offer TDF/FTC as PrEP. Study participants are followed 
for a period of 12 months. Those with pregnancy during 
the 12-month follow-up are counselled about HIV risk-re-
duction during pregnancy, offered PrEP and followed 
through to pregnancy outcome (regardless of PrEP use).
Population
ZINK participants are women aged 18–35 years who are 
HIV-negative with personal or partner plans for preg-
nancy with an infected or unknown serostatus partner. 
Women are recruited in Durban, KwaZulu-Natal, South 
Africa where nearly 40% of women who attend ante-
natal clinics test positive for HIV infection.28 PrEP is 
currently contraindicated for use by pregnant women 
in South Africa, due to local concerns regarding safety 
outlined by the South African Health Products Regula-
tory Agency (SAHPRA, formerly known as the MCC).29 
Due to challenges recruiting HIV-serodifferent couples in 
this setting, we recruit women as individuals30; however, 
women are invited to bring their partners to the study site 
for counselling and information.
Recruitment for this study is through fieldwork teams 
reaching out directly to women at local Department of 
Health primary healthcare clinics within the eThekwini 
District, gathering spots near the research site (such as 
hair salons and service queues), and through word-of-
mouth promotion from enrolled participants and others 
who know of the study. We are also planning community 
events in consultation with our affiliate Community Advi-
sory Board (CAB). Recruitment began in November 2017 
and is expected to last 30 months.
study aims and outcomes
The primary aims of the study are to: (1) determine PrEP 
uptake and adherence among all enrolled participants 
(by self-report, electronic monitoring, plasma and blood 
samples), (2) determine PrEP adherence among women 
who take PrEP during the periconception period and 
pregnancy and (3) explore adherence facilitators and 
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inform our conceptual framework for periconception 
PrEP uptake and adherence.27 Additional outcomes of 
interest include uptake of safer conception strategies 
including CHCT, ART for the infected partner and contra-
ception uptake for those who decide not to conceive after 
careful consideration. We also measure clinical outcomes 
including HIV seroconversion rates, pregnancy outcomes 
(eg, miscarriage, stillbirth and live birth) and infant 
outcomes (eg, weight, length and observed congenital 
anomalies).
Eligibility criteria
Study inclusion and exclusion criteria are presented in 
box 1 and include (via self-report) being woman; between 
ages 18 and 35 years; reporting an HIV-seropositive or 
unknown HIV serostatus partner; not on long-acting 
contraception (IUD (Intrauterine Device), injectable or 
implanted contraception); and personal or partner plans 
to have a child within the next year. Interested women 
are screened for infertility by history31 and participants 
who fail to meet the fertility criteria are considered inel-
igible. Women who are eligible based on the self-report 
data complete biological screening. They are eligible to 
enrol in the study if they test negative for pregnancy and 
HIV and are not co-enrolled (checked via fingerprint32) 
in other research studies that may conflict with our proce-
dures (eg, vaccine trials, PrEP projects and so on).
Informed consent procedures
Interested women are asked to complete a brief verbal 
informed consent prior to completing the screening ques-
tions (box 1). Women are eligible after completing the 
screening questions will be invited to complete an initial 
written informed consent where the secondary, biological 
screening process will be explained (box 1). If women 
are eligible for study enrolment, they will be invited to 
complete an in-depth informed consent process for study 
enrolment and participation.
The Research Assistants will use informed consent docu-
ments available in both English and isiZulu as a guide to 
discuss all the content in the informed consent with the 
potential participant. The consent forms will be reviewed 
orally by a study representative and the participant will 
be encouraged to ask detailed questions. Women who 
meet study inclusion/exclusion criteria and complete the 
informed consent process and give signed consent will 
then be enrolled.
study activities
Study activities and corresponding visit schedules are 
shown in table 1 and further explained below.
Counselling
At the enrolment visit, women are offered a package of 
safer conception counselling based on South African 
guidelines.33 These guidelines recommend that HIV-unin-
fected women who want to conceive a child with a partner 
living with HIV should encourage partner testing and 
serostatus disclosure within the partnership, encourage 
partner to initiate ART, delay sex without condoms until he 
achieves HIV RNA suppression or is on ART for 6 months, 
consider contraception to delay pregnancy until safer 
conception strategies implemented, limit condomless sex 
to peak fertility, and/or consider sperm washing, donor 
sperm and adoption as alternatives. In this study, safer 
conception counselling occurs at baseline and at each 
visit thereafter for non-pregnant women. Comprehensive 
counselling is performed by trained study counsellors in a 
group format, with the option of one-on-one counselling 
sessions based on participant preference and feasibility 
of convening a group. We developed and pilot tested 
locally relevant tools and visual graphics to communicate 
key concepts in prior studies34 35 (see figure 1A-C for key 
concepts).
Women who initiate PrEP participate in brief adher-
ence counselling and support sessions at each visit to 
discuss barriers to and promoters of adherence. A group 
format is pursued given interventions that target social 
networks and strengthen group ties have been used to 
empower marginalised groups and to effect health-re-
lated behaviour change related to HIV prevention.36–38 
box 1 Inclusion and exclusion criteria
Verbal screening inclusion criteria
 ► Female.
 ► Aged between 18 and 35 years.
 ► Sexually active.
 ► Likely to be fertile based on responses to reproductive history 
assessment.
 ► Personal or partner desire to have a child in the next year.
 ► With a stable (together for at least 6 months) partner, she reports 
as HIV-infected or HIV-serostatus unknown (if >1 desired pregnancy 
partner, we will ask her to identify the most likely pregnancy partner 
based on her own assessment of sexual frequency, fertility and so 
on).
 ► Able to participate in the informed consent process.
 ► Fluent in English or isiZulu.
secondary inclusion after informed consent
 ► Co‐enrolment in studies which may conflict with participation in this 
study.
 ► HIV-negative (rapid testing).
 ► Not pregnant (by urine beta-hCG testing).
Exclusion criteria
 ► HIV positive.
 ► Pregnant.
 ► No desire to have a child in the next 12 months.
 ► Living at or planning to relocate to a location incompatible with 
study participation in the next year.
 ► Active drug or alcohol use that, in the opinion of the research study 
team, would interfere with adherence to study requirements.
 ► Active illness requiring systemic treatment and/or hospitalisation 
within 30 days prior to study entry that in the opinion of the research 
study team, might otherwise interfere with adherence to study 
requirements.
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Participants will also have the option of participating in 
one-on-one counselling sessions based on their prefer-
ence and schedule.
laboratory
Participants complete beta-HCG urine pregnancy testing, 
individual HIV counselling and testing (HCT), and 
syndromic screening for STIs at each study visit. Study 
staff will follow-up with participants who seroconvert to 
promote linkage to care and conduct genotyping. Partic-
ipants with a positive pregnancy test are referred to ante-
natal care and those with STI symptoms are referred to a 
local clinic for treatment.
Women who choose to initiate PrEP undergo blood 
testing for renal function (creatinine) and for hepatitis B 
infection. Women with abnormal renal function (serum 
creatinine >89 µmol/L and estimated glomerular filtra-
tion rate (eGFR) <60 mL/min or serum creatinine >85 
µmol/L for pregnant women) or active hepatitis B infec-
tion (hepatitis B surface antigen positive) are instructed 
to stop PrEP.
Renal function testing is repeated quarterly in accor-
dance with CDC and WHO guidelines for safety moni-
toring. PrEP can be stopped at any point should there be 
the abnormal renal function as per the above definition. 
PrEP can be re-started if serum creatinine and/or eGFR 
levels return to normal. Pregnant women who decide to 
continue PrEP during pregnancy are retested for hepatitis 
Table 1 Study procedures for non-pregnant and pregnant participants
Procedures Enrolment M1 M3 M6 M9 M12
Counselling
  Safer conception counselling
  Adherence support if taking PrEP
Laboratory
  Urine pregnancy test*
  HIV rapid test
  STI symptom screen
  HBV serology if initiating PrEP
  Creatinine if initiating PrEP and quarterly while on PrEP
  Blood sample for tenofovir levels if on PrEP
Sociobehavioural data
  Sociodemographic information
  Brief questionnaire
  Full questionnaire
  Weekly SMS sexual behaviour data
  MEMS cap adherence data and questionnaire if on PrEP
  In-depth interviews with a subset of women
*Once pregnancy is diagnosed, women reconsent to participate in the study and are seen monthly for HIV testing and safety monitoring. 
They maintain a schedule for quarterly counselling and adherence support. A postpregnancy follow-up visit will assess pregnancy and infant 
outcomes.
HBV, hepatitis B virus; MEMS, Medication Event Monitoring System; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection. 
Figure 1 Locally-relevant images developed to convey 
key safer conception strategies in the safer conception 
counselling sessions. (A) Treatment as prevention. (Top panel) 
The man is not taking ART, has a high viral load and there is 
a high risk of transmitting to his partner. (Down panel) The 
man is taking ART, has a suppressed viral load and the risk 
of transmitting to his partner is minimized. (B) PrEP. The man 
is not taking ART, has a high viral load and there is a high risk 
of transmitting to his partner. In (B), the woman is taking PrEP 
which protects her from acquiring HIV. (C) Timing condomless 
sex to peak fertility. In this image, the couple is evaluating 
a calendar to time condomless sex to peak fertility. ART, 
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B and kidney function at the time of their positive preg-
nancy test. All women who chose PrEP during pregnancy 
undergo renal function testing every 3 months until preg-
nancy outcome.
Questionnaires
At month 0, 6 and 12, a full questionnaire is administered 
to assess constructs within our conceptual framework for 
periconception risk behaviour (eg, risk perception, repro-
ductive autonomy and HIV stigma)27 (online supple-
mentary appendix 1). Constructs are measured using 
instruments validated in this setting. Questionnaires are 
administered via face-to-face interviews with a trained 
research assistant fluent in English and isiZulu, which is 
the dominant local language. At month 3 and 9, a brief 
questionnaire is administered to explore safer conception 
behaviours including self-reported partner HIV status, 
delay of sex without condoms until the partner on ART is 
virologically suppressed, and access to additional services 
such as sperm washing.
At the enrolment visit, participants are asked to sign 
up for a weekly four-question SMS sexual behaviour 
survey delivered to their mobile phone. The questions 
and response options are listed in table 2. These pass-
word-protected SMS-reported sexual behaviour data will 
allow for the measurement of adherence relative to HIV 
exposure.39
PrEP use
Participants who choose to use PrEP are offered oral, 
daily TDF/FTC PrEP (provided by Gilead) according to 
US CDC guidelines for periconception PrEP and WHO 
Guidelines for PrEP use among those at substantial risk 
for acquiring HIV.40 41 Women are counselled to use PrEP 
for 7 days (as per WHO 2016 guidance) before engaging 
in sex without condoms or other backup protection. 
Women are counselled to continue PrEP for at least 28 
days after the last HIV exposure.
PrEP uptake is defined as the proportion of enrolled 
women who collect at least 1 month’s supply of PrEP 
within the first 12 months of study participation. Women 
may choose to initiate/discontinue PrEP at any time 
during the periconception period. At each quarterly visit, 
a 90-day prescription is given to participants (non-preg-
nant and pregnant) who chose to use PrEP. Women who 
become pregnant may choose to continue or initiate PrEP, 
with a plan to continue through to pregnancy outcome or 
until her risk is resolved.
Participants taking PrEP are provided AARDEX Medi-
cation Event Monitoring System (MEMS), a bottle cap 
with an electronic chip that clocks bottle openings. At 
each study visit, MEMS data will be downloaded by study 
staff and a questionnaire will be completed to evaluate for 
self-reported adherence. We will evaluate adherence to 
PrEP through plasma tenofovir (TFV) and diphosphor-
ylated tenofovir (TFV-DP) levels in dried blood spots. 
Samples will be collected 3 months after PrEP initiation 
and at quarterly visits thereafter. Detectable (>0.31 ng/
mL) TFV indicates at least one dose in the prior 7 
days, >10 ng/mL indicates dosing in the last 2–3 days 
and >40 ng/mL indicates dosing in the last 24 hours and 
is associated with HIV protective efficacy.42 43 We antici-
pate performing the DBS TNF-DP assay on 20 percent of 
the total number of samples. The TNF-DP data will give a 
sense of longer-term adherence and may help assess the 
‘white coat’ effect in this sample.44–46 Adherence ques-
tions at each visit and sexual behaviour data will be used 
to evaluate for adherence relative to HIV exposure or 
‘prevention-effective’ adherence.18
In-depth qualitative individual interviews
In-depth qualitative individual interviews will be 
conducted with a subset of up to 25 women based on a 
‘purposeful sampling’ framework.47 Trained research 
assistants will conduct initial (up to 6 months after enrol-
ment) and exit qualitative interviews to explore factors 
affecting PrEP uptake and adherence during periconcep-
tion and pregnancy. Pregnant and non-pregnant women 
will be selected from three groups of roughly equal distri-
bution including (1) those who did not choose PrEP 
as part of a safer conception strategy, (2) those who 
chose PrEP and/or have detectable plasma TFV and/
or >80% MEMS adherence and (3) those who chose PrEP 
but have undetectable plasma TFV and/or <80% MEMS 
adherence. Additionally, we will follow women over the 
course of the study and offer repeat event-triggered quali-
tative interviews after major life events such as pregnancy, 
major change in partnership (eg, participation in CHCT, 
disclosure and separation from current partner) or 
change in PrEP use. Based on our conceptual framework, 
we assume that uninfected women who want to have a 
child with an infected or unknown serostatus partner 
will experience individual, couple and community-level 
factors that influence PrEP initiation and adherence 
Table 2 Weekly SMS sexual behaviour survey delivered to 
their mobile phone in their language of choice (English or 
isiZulu)
Question Response options
Did you have sex in 
the past 7 days?
1. Yes
2. No → stop questionnaire
3. I prefer not to answer
Which partner(s)? 1. Healthy baby partner
2. Other partner(s)
3. Healthy baby and other partners
4. I prefer not to answer
I used a condom… 1. Every time
2. Some of the time
3. Never
4. I prefer not to answer
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behaviour. At the individual level, she may have excellent 
knowledge of safer conception strategies, be optimistic 
about PrEP efficacy and perceive herself to be at high risk 
for acquiring HIV. However, on the dyadic level, she and 
her partner may not communicate or trust one another, 
making it hard for her to adhere to daily medication. If 
she feels that childlessness and/or being HIV-infected is 
highly stigmatised in the community, she may be more 
motivated to participate in periconception PrEP (online 
supplementary appendix 2.) By collecting qualitative data 
as well as quantitative covariates that reflect the constructs 
of this framework, our mixed methods data will allow us 
to adapt this framework as appropriate to inform inter-
ventions for women seeking HIV prevention during peri-
conception and pregnancy.
Pregnant participants
Participants who become pregnant during the study 
have the option to continue participating in the study 
(per GCP guidelines a woman who becomes pregnant 
must reconsent to participate in this study). If a woman 
has not chosen PrEP, then she can choose to start. If she 
has already chosen PrEP, then she can choose whether 
or not to continue. Pregnant participants are referred 
to their local clinic for antenatal follow-up and care. 
Pregnant participants receive counselling regarding 
the risks and benefits of using PrEP during pregnancy. 
Women who plan to reduce HIV exposure without PrEP 
(eg, partner on ART with suppressed viral load, routine 
condom use and HIV-negative partner) will be encour-
aged to pursue these methods of risk reduction. Women 
who cannot confidently implement strategies to reduce 
HIV acquisition risk will be supported to start or to 
continue to use PrEP, during pregnancy. This approach 
is consistent with US CDC and WHO guidelines for 
PrEP use,40 41 but is not part of South African guidelines 
where TDF/FTC as PrEP is contraindicated for use in 
pregnancy given safety concerns.29 At the conclusion of 
pregnancy, women will be asked about the pregnancy 
outcome and their clinical charts will be reviewed to 
collect additional relevant data, such as live birth, still-
birth or miscarriage.
Women who become pregnant during the first 12 
months of follow-up will be asked to bring their child 
in for evaluation by the study doctor at their final visit 
(within 3 months of pregnancy end), to document birth 
date, outcomes and conduct an examination to evaluate 
for any congenital abnormalities. The study team will also 
ask permission to contact the labour and delivery unit 
and/or paediatrician for additional details. For women 
who do not return for this visit, loss to follow-up proce-
dures will be followed including contacting the partici-
pant, home visits, and reviews of the medical record at the 
facility where she sought antenatal care and/or planned 
to deliver. Permission to conduct off-site visits and access 
healthcare records will be obtained during the pregnancy 
consenting process.
Women will be reimbursed 250 South African Rand 
(~20 US$) per scheduled visit consistent with South Afri-
ca’s local guidance.
Patient and public involvement
Years of mixed methods research with men and women 
affected by HIV informed this proposal.114 19 28 47 48 In 
addition, the study team consulted with MatCH Research 
Unit’s affiliate CAB who informed our understanding 
and appreciation of community members’ personal 
and familial experiences related to a woman’s choice to 
have a child with a partner who is living with HIV or with 
an unknown serostatus partner. They also aided in our 
understanding of women’s need for, and the complexities 
related to, informed and supported prevention strategies 
to reduce periconception HIV acquisition risk. The CAB 
advised the research team on appropriate recruitment 
venues, recommended that study team members present 
the study at community council meetings, and posted 
study flyers at clinics and community gathering spots.
In addition to recruitment efforts by the study team 
and the CAB, the participants themselves are involved in 
ongoing word-of-mouth recruitment. The results of the 
study will be disseminated to participants at community 





We will calculate the proportion (and 95% CI) of women 
who initiate PrEP. PrEP uptake is defined as the proportion 
of enrolled women who collect at least 1 month’s supply 
of PrEP within the first 12 months of study participation. 
We will describe and compare baseline characteristics 
among those initiating PrEP versus those not initiating 
PrEP and test for differences in the distribution of char-
acteristics in the two groups using the t-test or Wilcoxon 
rank sum test, as appropriate, for continuous variables 
and Χ2 or Fisher exact test as appropriate for categorical 
variables. Log-binomial regression will be used to model 
the association between characteristics of interest (eg, 
partner HIV serostatus) and PrEP initiation and to calcu-
late unadjusted risk ratios and 95% CIs. Covariates that 
are marginally associated with PrEP initiation at p<0.1 will 
be considered for inclusion in multivariable models and 
adjusted ORs and 95% CIs will be calculated.
PrEP adherence
Adherence implementation will be defined as the number 
of MEMS cap openings divided by the total number of 
doses prescribed over the study interval in the pericon-
ception period. Adherence persistence refers to the dura-
tion of PrEP use, defined as the time (in weeks) from 
PrEP initiation to either the first interval period of at least 
1 week with no openings during a period of intended 
overage, undetectable plasma TFV or study completion. 
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(eg, if the woman remains at risk for HIV with respect 
to sexual behaviour, partner serostatus and partner viral 
suppression).18
The primary adherence outcome is defined among 
PrEP initiators as a protective (>40 ng/mL) plasma TFV 
concentration, measured quarterly (binary outcome). 
Secondary adherence outcomes are based on electronic 
monitoring with MEMS caps. We will determine the mean 
and median number of pills taken as well as patterns of 
adherence (gaps). We will consider MEMS adherence as 
a binary outcome defined as taking >80% of prescribed 
doses based on biologic plausibility and prior studies.48–53 
We will also explore adherence as a continuous outcome 
and will determine longitudinal trends in adherence 
through monthly assessments of median (IQR) adher-
ence and adherence gaps of at least 72 hours and PrEP 
use in the context of HIV-exposure.
For the prevalence of PrEP adherence (binary), we 
will use a log-binomial regression model (intercept term 
only) with generalised estimating equations (GEE) in 
the setting of repeated measurements. We will extend 
this model to include baseline and time-updated charac-
teristics of interest to estimate unadjusted relative risks 
and 95% CI. For continuous adherence outcomes using 
MEMS cap data, we will describe the distribution of adher-
ence and compare mean and median adherence levels 
across the full periconception period in those exposed 
versus not exposed to baseline and time-updated factors 
of interest.
Additional outcomes
We will also describe, as additional outcomes, pregnancy 
incidence, HIV seroconversion (and compare rates 
among those taking and adherent to PrEP with those 
who do not take or adhere to PrEP) and all pregnancy 
outcomes. The samples size will be too small to carry out 
adjusted analyses, but bivariate associations will inform 
factors that affect the uptake of and adherence to PrEP. 
We will also evaluate the use of other safer conceptions 
strategies (eg, CHCT, delay of sex without condoms until 
a partner tests for HIV and is either HIV-uninfected or 
HIV-positive, accessing ART and suppressed, and access 
of additional services such as sperm washing.)
Longitudinal quantitative data and serial in-depth inter-
views with initially high-adhering and low-adhering partic-
ipants as well as participants who do not initiate PrEP will 
explore barriers to and promoters of PrEP uptake and 
adherence while informing our conceptual framework. 
Grounded theory methods will be used to analyse quali-
tative interview data. These methods lay out a systematic 
set of inductive procedures for developing categories 
of information, organising data in terms of these cate-
gories through coding, connecting the categories and 
deriving from these connections an empirically grounded 
theory. We will also use structural equation modelling to 
examine the associations and putative causal pathways 
among the hypothesised determinants of adherence as 
described in the conceptual framework (eg, individual 
level motivations such as parenthood motivation, dyadic 
factors such as relationship power, and community-level 
factors such as functional support).
Clinical outcomes relating to PrEP safety
We will describe clinical outcomes relating to the safety 
of PrEP use in pregnancy including pregnancy outcomes 
(miscarriage, stillbirth and live birth) and infant outcomes 
inclusive of weight, length, head circumference and 
any noted congenital anomalies. Incidence rates will be 
compared across women exposed/not exposed to TDF/
FTC as PrEP and also compared with population norms.
Power and sample size considerations
We will calculate the proportion of women who initiate 
PrEP over a 12-month period. A target sample size of 
350 women produces a 95% CI width of 9.9% when the 
percent of women initiating PrEP is 70% and a 95% CI 
width of 10.5% when the percent of women initiating 
PrEP is 50% (eg, 70% (95% CI 65% to 75%)), providing 
reasonable precision for an estimate of PrEP uptake.
Among women who initiate PrEP, we will calculate 
the proportion of women adherent to at least 80% of 
prescribed doses in the past month. For this and other 
binary adherence outcomes, a target sample size of 245 
women initiating PrEP produces a 95% CI width of 10.4% 
when the percent of women who are high adherers to 
PrEP is 80%. For continuous adherence outcomes, this 
sample size produces a two-sided 95% CI with a distance 
from the mean to the limits that is equal to 0.126 SD when 
the estimated SD is 1.000.
Lost to follow-up data
Data from women lost to follow-up will be censored at 
last contact. In addition, to adjust for potential bias due 
to loss to follow-up among pregnant women, we will 
conduct a sensitivity analysis using the inverse probability 
of censoring weighting.54 55
Ethics and dissemination
This study team has considered the ethical issues in 
line with ICH-GCP (The International Conference on 
Harmonization of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use - Good Clinical 
Practice) guidelines. Given normative guidance for PrEP 
use in pregnancy in South Africa, the DSMB will review 
safety data including adverse infant outcomes (preterm 
birth (<37 weeks gestation), stillbirths, low birth weight 
(<2500 g) and observed congenital anomalies). Study 
clinicians will carefully monitor adverse events in women 
choosing PrEP and pregnant women at all scheduled 
study visits. All data on pregnancy use and TDF/FTC 
exposure are reported to the Antiretrovirals in Pregnancy 
Registry (http://www. apregistry. com/). Study results will 
be disseminated at national and international confer-
ences and in peer-reviewed journals. The trial findings 
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The protocol has been approved by the Human 
Research Ethics Committee at the University of the 
Witwatersrand (Pretoria, South Africa) and the Insti-
tutional Review Board of Partners Healthcare (Boston, 
Massachusetts, USA). The protocol is registered with 
the South African Health Products Regulatory Agency 
(SAHPRA), MCC#20170131) and at  ClinicalTrials. gov 
(NCT03194308).
Results will be presented to local health officials 
and stakeholders at meetings. Investigators will share 
the results at meetings and in manuscripts. De-identified 
quantitative data will be made available. Qualitative data 
will not be made available due to challenges to redacting 
identifiers in a potentially-stigmatised population of 
HIV-exposed women planning pregnancy.56 We will aim to 
follow STROBE guidelines in the presentation of results.
ConClusIon
For women who cannot depend on a partner to test, 
initiate and adhere to ART, and suppress HIV-RNA, 
condomless sex puts her at risk of acquiring HIV and 
increases the risk of perinatal transmission to her child. 
This study will provide important objective information 
regarding women’s choices and use of PrEP and other 
safer conception strategies in this context. We will also 
collect additional safety data regarding TDF/FTC-ex-
posed pregnancies.
trial status
The study is currently recruiting participants.
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